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Introduction. Adrenal glands play a major role in the control of blood pressure and mild defects of steroidogenesis and/or
inappropriate control of mineralocorticoid production have been reported in high blood pressure (HBP). Patients andMethods. We
used a specific protocol for the evaluation of 100 consecutive patients with inappropriate or recent onset HBP. Specificmethods were
used to confirm HBP and to diagnose secondary forms of HBP. In addition we tested adrenal steroidogenesis with the common
cosyntropin test, modified to include the simultaneous measurement of renin and aldosterone besides 17-hydroxyprogesterone
(17OHP) and 11-deoxycortisol (S). Results. Secondary forms of HBP were diagnosed in 32 patients, including 14 patients with
primary hyperaldosteronism (PA) (14%) and 10 patients with pheochromocytoma (10%). Mild defects of the 21-hydroxylase
(21OHD) and 11-hydroxylase (11OHD) enzymes were common (42%). ACTH-dependent aldosterone secretion was found in most
patients (54%) and characteristically in those with mild defects of adrenal steroidogenesis (>60%), PA (>75%), and otherwise in
patients with apparent essential HBP (EHBP) (32%). Discussion. Mild defects of adrenal steroidogenesis are common in patients
with HBP, occurring in almost half of the patients. In those patients as well as in patients with apparent EHBP, aldosterone secretion
is commonly dependent on ACTH.
1. Introduction
HBPoccurs inmore than 25%of the adult western population
and is a major determinant of mortality, with cardio- and
cerebrovascular disease accounting for 30–50% of all deaths
[1].
Until recently, HBP was assumed to be idiopathic in
over 90% of the cases, and the search for the etiology was a
futile clinical exercise in most instances [2]. As an example
of changing medical paradigms, secondary forms of HBP,
mainly PA, are now considered to account for up to 15% of
all cases [3].
Adrenal glands play a major direct role in water and salt
balance,mineralocorticoids and glucocorticoids, and in heart
output and vascular tone, catecholamines; they are therefore
a major determinant of blood pressure levels in normal
conditions [3–5]. Specific adrenal diseases like PA, Cushing’s
syndrome, pheochromocytoma, and some cases of congenital
adrenal hyperplasia (CAH) and glucocorticoid-remediable
aldosteronism (GRA) are well recognized forms of secondary
HBP [1–7]; however, except for PA, all are deemed to be very
rare.
A more general involvement of the adrenals may occur
in HBP. Recent research identifies mild defects of the final
steps of glucocorticoid and/or mineralocorticoid synthesis,
namely, defects of the 11𝛽-hydroxylase enzyme and abnormal
control of aldosterone secretion, ACTH-dependent aldos-
terone secretion, as common and related phenomena in
patients with HBP [8–12]. We tested adrenal steroidogenesis
andmineralocorticoid production, using the common cosyn-
tropin test, modified to include the measurement of renin
and aldosterone, besides cortisol, 17OHP, and S, in patients
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with recent onset or inappropriate HBP, as defined by Kaplan
[2].
2. Patients and Methods
We selected, from the Outpatient Endocrine Clinic, patients
with inappropriate HBP as defined by Kaplan [2], that is,
(a) HBP beginning before 20 or after 50 years; (b) HBP
with very high levels to begin with, with early evidence of
target organs lesions, or requiring from the beginning several
antihypertensive drugs to control blood pressure levels; (c)
HBP with special clinical clues suggesting a secondary form,
including hypokalemia, hypertensive crisis, and vascular
bruits over the renal areas; (d) family history of early onset
HBP.
Etiologic factors of HBP may be apparent only during
the early stages of the disease, since with time HBP tends
to become fixed and dependent on increased peripheral
vascular resistance [2]. We also included patients with recent
onset HBP, defined as less than 5 years since diagnosis.
These patients were admitted to the Endocrine Inpatient
Department after at least a weekend with only Nifedipine
used to treat HBP or at least three weeks after suspending
spironolactone use and entered into a specific evaluation
protocol: (1) baseline, including serum glucose, urea, crea-
tinine, ionogram, calcium, phosphate, magnesium, thyroid
and parathyroid function, insulin, ACTH, cortisol, renin,
aldosterone, urinary catecholamines, metanephrine and nor-
metanephrine, EKG, chest radiograph, echocardiogram,
renal sonography, and the 24 h measurement of blood pres-
sure levels (24HBP); (2) the saline suppression test, 2 L of
normal saline, iv, in four hours with measurement of renin
and aldosterone before and after the procedure; (3) the
corticotropin releasing hormone test measuring ACTH and
cortisol before and at 5, 10, 15, 30, 60, and 120min after
the iv administration of corticotropin releasing hormone
100 𝜇g; (4) the clonidine test withmeasurement of serum cat-
echolamines, metanephrines, and normetanephrines, before
and 3 h after the administration of 300mg of clonidine po; (5)
oral tolerance test with 75 g of glucose and measurement of
serum glucose and insulin at times 0, 30, 60, 90, and 120min;
(6) personality evaluation using the Minnesota Multiphase
Personality Inventory (MMPI). A modified version of the
common cosyntropin test was also administered: 250 𝜇g of
cosyntropin (1-24 ACTH) was administered iv, at time 0, and
measurement before and at 30 and 60min after of cortisol,
17OHP, S, renin, and aldosterone was obtained.
This protocol was modified according to the specific clin-
ical characteristics of the patients, and therefore not all tests
were done in every patient, while some specific tests like
the furosemide and the captopril tests or the dexameth-
asone suppression test were sometimes performed. Imaging
methods followed as appropriate.
All serum measurements were performed in duplicate at
the Clinical Pathology Department using standard method-
ology and commercially available kits. More specifically
radioimmunoassay (RIA) was used for the measurement
of 17OHP (Coat-A-Count 17𝛼-OH Progesterone, Siemens),
aldosterone (Coat-A-Count Aldosterone, Siemens), and S
(DIAsource 11-deoxycortisol-RIA-CT), an immunoradiomet-
ric assay (IRMA) for renin (DIAsource Renin-IRMA), while
for cortisol measurement a colorimetric enzyme-linked
immunoassay was used (CLIA) (Bayer Diagnostics ADVIA
Centaur). Intra- and interassay variation were always <10%,
and regarding 17OHP and S assays, cross reactivity was <6%.
Reference baseline decubitus values are as follows: cortisol 3–
23 𝜇g/dL, 17OHP 0–5 ng/mL, S 0–5 ng/mL, renin 1–20 𝜇U/
mL, and aldosterone 10–160 pg/mL.
The statistical package for the Social Sciences software
(IBM SPSS19, New York) was used for the analysis. Results
are expressed as the mean ± standard deviation (𝜇 ± 𝜎) or as
% as appropriate. The normal distribution of the continuous
variables was verified with the Kolmogorov-Smirnov test
(KS), or the log-transformed variables were used; however
when no difference was found, results regarding the non-
transformed variable are presented.The Chi-squared test, the
Student 𝑡 test, or factorial ANOVA was used to compare
groups and regression analysis to explore the relation between
continuous variables.
3. Results
We studied 112 consecutive patients. However for several
reasons, the protocol was too incomplete to be useful in 12
patients andwe now report the results of 100 patients. Patients
were mainly female (66%) and middle-aged (46 ± 15 years).
HBP had been diagnosed 8 ± 8 years before. Results of the
diagnostic workup of the patients are presented in Figure 1.
In fifteen patients (15%) the diagnosis of HBP was
specifically excluded. In hospital and afterwards during usual
life, 24HBP without any medication was normal, with no
evidence of target organ lesions.
A secondary form of HBP was diagnosed in 32 cases
(32%). There were fourteen (14%) cases of PA, increased
aldosterone/renin ratio, no suppression of aldosterone lev-
els in the saline test, and from these 7 were adenoma,
single nodular lesion in the adrenal with a positive 131I-
iodomethylnorcholesterol (131IMNC) scan and decreased
aldosterone after 4 h of deambulation, and 7 were bilateral
hyperplasia, no nodular lesion in the CT scan of the adrenals,
bilateral hyperfixation on the (131NIMC) scan, and increased
aldosterone after 4 h deambulation. In ten cases (10%) the
diagnosis of pheochromocytoma was established, increased
urinary metanephrine and/or normetanephrine levels, no
suppression of metanephrine and/or normetanephrine levels
in the clonidine test, a nodular lesion on the adrenals CT scan,
and a positive 123I-metaiodobenzylguanidine (123MIBG)
scan. There were four cases (4%) of HBP secondary to renal
disease, renal disease with increased serum creatinine levels,
two cases (2%) of secondary hyperaldosteronism (SA), one
with documented renal stenosis and the other probably in
relation to contraceptive use, one case (1%) of Cushing’s
disease with no suppression of cortisol levels after prolonged
low dose dexamethasone, suppressed cortisol after prolonged
high dose dexamethasone and a pituitary lesion on sellar
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Table 1: Cosyntropin (1–24 ACTH) test (250mg, iv at time 0).
0min 30min 60min
Cortisol [3–23 𝜇g/dL] 16 ± 7 [6–48] 38 ± 11 [20–51] 39 ± 10 [10–51]
17OHP [0–5 ng/mL] 2 ± 1 [1–5] 8 ± 6 [1–39] 8 ± 6 [1–38]
S [0–2 ng/mL] 2 ± 1 [1–8] 6 ± 4 [2–25] 7 ± 4 [2–19]
Renin [1–20 𝜇U/mL] 10 ± 20 [1–149] 11 ± 21 [1–142] 11 ± 18 [1–121]
Aldosterone [10–160 pg/mL] 114 ± 171 [2–859] 221 ± 313 [10–1,628] 334 ± 522 [5–3,656]
Conversion factors are as follows: cortisol 𝜇g/dL × 27.59 = cortisol nmol/L; 17OHP ng/mL × 3.026 = 17OHP nmol/L; S ng/mL × 2.887 = S nmol/L; aldosterone
pg/mL × 0.002774 = aldosterone nmol/L.
100 patients
No HBP
15 patients
Secondary HBP
32 patients
Renal disease
4 patients
SA
2 patients
Cushing’s disease
1 patient
Aortic regurgitation
1 patient
Pheochromocytoma
10 patients
PA
14 patients
Essential HBP
53 patients
HBP: High blood pressure
SA: Secondary aldosteronism
PA: Primary aldosteronism
Figure 1: Diagnostic workup of the patients. HBP, high blood
pressure; PA, primary aldosteronism; SA, secondary aldosteronism.
NMR, and one case (1%) of isolated systolic HBP with
documented aortic regurgitation.
Essential HBP (EHBP) was diagnosed in the remaining
53 cases (53%). However even in these patients one or
more presumptive contributory mechanisms for HBP could
be identified in all but nine cases, which guided therapy
selection: obesity (26 patients), hyperinsulinism (7 patients),
type 2 diabetes (18 patients), chronic stress (11 patients),
contraceptive use (2 patients), and possible reaction to
antidepressive drugs (3 patients).
The cosyntropin test was not performed in the 15 patients
with no HBP, neither on the 10 patients with a diagnosis of
pheochromocytoma nor on 10 patients with apparent EHBP.
Therefore the test was only preformed in 65 cases. Results of
the cosyntropin test are presented in Table 1.
The distribution of 17OHP and S values at baseline and
pos-stimulation at 60min are presented in Figure 2. The
relation between skewness and kurtosis suggests that the
baseline 17OHP distribution is unimodal, while the same is
not true regarding the distributions of baseline S or pos-
stimulated levels of either 17OHP or S [13]. Besides, baseline
and pos-stimulation levels of 17OHP and S are not normally
distributed (K-S z between 1.341 and 2.740, 𝑃 < 0.05).
Glucocorticoid steroidogenesis was intrinsically related that
is, baseline cortisol was directly related to 17OHP (𝑟 = 0.388,
𝑃 < 0.05) and to S (𝑟 = 0.329, 𝑃 < 0.05), while this
was not true regarding mineralocorticoid steroidogenesis,
no significant relation of renin and aldosterone, and neither
were glucocorticoid and mineralocorticoid steroidogenesis
related, no significant relation of baseline renin or aldos-
terone with cortisol, 17OHP or S.
Criteria for the 21-hydroxylase defect (21OHD) are well
defined and include a 17OHP response equal to or greater
than 10 ng/mL in the cosyntropin test [14, 15]. Although in
every case baseline levels were within the reference range,
using this criterium, 10 out of 65 patients (15%) at 30min and
17 out of 65 patients (26%) at 60min presented preliminary
evidence for a mild defect of the 21-hydroxylase enzyme.
Taken together 21 out 65 patients (32%) presented such
evidence. As noted this defect was not apparent at baseline
levels. In fact baseline 17OHP levels are only weakly related
to pos-stimulated 30min levels (𝑟 = 0.232, 𝑃 < 0.1) or to
pos-stimulated 60min levels (𝑟 = 0.228, 𝑃 < 0.1) while
pos-stimulated 30 and 60min levels are strongly related (𝑟 =
0.978, 𝑃 < 0.001).
Criteria for the 11-hydroxylase defect (11OHD) are less
well defined, but most authors indicate an S response equal
to or greater than 8 ng/mL in the same test [15, 16]. Since the
baseline or pos-stimulated ratio of S/17OHP is always close
to 1 [15], we more strictly defined such a defect as a response
greater than 10 ng/mL. Only 3 patients presented slightly
increased baseline levels. Using that criterium however, 7 out
of 65 patients (11%) at 30min, 11 out of 65 patients (17%)
at 60min, and taken together 14 out of 65 patients (22%)
presented preliminary evidence for a mild defect of the 11-
hydroxylase enzyme. Baseline levels were related to pos-
stimulation levels, at 30min (𝑟 = 0.467, 𝑃 < 0.001) and at
60min (𝑟 = 0.429, 𝑃 < 0.005), while pos-stimulated levels
were strongly related to each other (𝑟 = 0.926, 𝑃 < 0.001).
A defect of the 11-hydroxylase enzyme may also result
in increased 17OHP levels, besides increased S levels; in
fact this occurs in 8 out of the 14 patients (57%) with a
postulated 11OHD; if we therefore exclude such patients from
the category of 21OHD, we find that 14 out of 65 patients
(22%) presented evidence for a mild 11OHD and 13 out of 65
(20%) presented evidence for a mild 21OHD.
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Figure 2: (a) Histogram of baseline 17-hydroxyprogesterone (17OHP) distribution. (b) Histogram of 17-hydroxyprogesterone (17OHP)
distribution at 60min after 250 𝜇g of cosyntropin iv. (c) Histogram of baseline 11-deoxycortisol (S) distribution. (d) Histogram of 11-
deoxycortisol (S) distribution at 60min after 250 𝜇g of cosyntropin iv.
Regarding the 13 patients with apparent mild 21OHD
most patients presented EHBP, 12 patients, but it was also
found in one patient with PA-hyperplasia, so that the 21OHD
is found in 28% of the patients with EHBP (12 out of 43).
Regarding the 14 patients with apparent mild 11OHD most
patients presented EHBP, 9 patients, but it was also found
in 2 patients with PA-adenoma and in 1 patient with PA-
hyperplasia and in 2 patients with HBP secondary to renal
disease, so that the 11OHD is found in 20% of the patients
with EHBP (9 out of 43) and in 21% of PA (3 out 14).
To emphasize the differences, characteristics of steroido-
genesis in patients without defect, with the 21OHD and with
the 11OHD, are indicated in Table 2.
For patients with apparent mild 21OHD, (1) the evidence
for the defect is given by the increased 17OHP response
and because of a much decreased cortisol/17OHP ratio
at 60min, that is, much decreased cortisol production in
relation to 17OHP; (2) interestingly enough these patients
present slightly but significantly increased pos-stimulated S
levels, albeit to a much lesser degree than patients with the
11OHD.
For patients with the apparent mild 11OHD, (1) the defect
is evident by the increased S response and accessorily because
of higher baseline levels of S and a much decreased cortisol/S
ratio at 60min, that is,much less cortisol produced in relation
Table 2: Steroidogenesis in patients with no defect (A) or with the
21OHD (B) or 11OHD (C).
No defect
(A)
(38)
21OHD
(B)
(13)
11OHD
(C)
(14)
17OHP baseline (ng/mL) 2 ± 1 2 ± 1 3 ± 13c
17OHP 30min (ng/mL) 5 ± 2 10 ± 1a,c 15 ± 11b,c
17OHP 60min (ng/mL) 5 ± 2 11 ± 2a,c 15 ± 11b,c
C17OHP 60min1 8.7 ± 5.4 4.3 ± 1.6a 3.2 ± 1.8b
S baseline (ng/mL) 2 ± 1 2 ± 1 4 ± 2b
S 30min (ng/mL) 4 ± 1 6 ± 2a,c 12 ± 6b,c
S 60min (ng/mL) 5 ± 2 6 ± 1a,c 14 ± 3b,c
CS 60min2 8.1 ± 3.0 7.0 ± 2.6c 3.0 ± 0.5b,c
1C17OHP60min cortisol/17OHP ratio at 60min, arbitrary units; 2CS 60min
cortisol/S ratio at 60min, arbitrary units; asignificant differences between
groups B andA; bsignificant differences between groupsC andA; csignificant
differences between groups C and B; in every case post hoc analysis when
analysis of variance between the three groups revealed significant differences.
to S; (2) these patients with the 11-hydroxylase defect also
present evidence of the 21-hydroxylase defect, and this is not
unexpected; that is, a distal defect does result in a proximal
increase of precursor compounds, like 17OHP.
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HBP: High blood pressure
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11OHD: 11-hydroxylase defect
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Figure 3: Abnormal steroidogenesis in patients with essential high blood pressure and in those with primary hyperaldosteronism. ADA,
ACTH-dependent aldosterone secretion; HBP, high blood pressure; PA, primary aldosteronism; SA, secondary aldosteronism; 21OHD, 21-
hydroxylase defect; 11OHD, 11-hydroxylase defect.
Baseline and pos-stimulated levels of either cortisol,
renin, or aldosterone were not significantly different regard-
ing patients with or without postulated defects of steroidoge-
nesis.
As noted in Table 1, a marked aldosterone response was
found in the cosyntropin test. In fact the peak/baseline ratio
for aldosterone is even superior to that for cortisol. Also as
noted in Table 1, this response is clearly not renin dependent,
since no major change is found regarding renin levels and in
fact, renin levels at baseline, at 30min and at 60min are not
significantly different. The seemingly inescapable conclusion
is therefore that ACTH (or at least the synthetic analog 1-24
ACTH) is the relevant stimulus for the aldosterone response.
Interestingly enough baseline levels of renin and aldosterone
were not significantly related.
Using an arbitrary criterium, an aldosterone response
greater than that of cortisol at 60min, that is, an aldosterone
at 60min/baseline aldosterone > cortisol at 60min/baseline
cortisol, 35 out of 65 patients were found (54%) to present an
aldosterone response to ACTH greater than that of cortisol,
pointing to the relevance of ACTH in aldosterone secretion.
This “abnormal” aldosterone response is found in 64% of
the patients with evidence for the 11𝛽-hydroxylase defect (9
out of 14), in 62% of the patients with evidence for the 21-
hydroxylase defect (8 out of 13), in 86% of the patients with
PA-hyperplasia (6 out 7), in 71% of the patients with PA-
adenoma (5 out of 7), and in 100% of the patients with HBP
secondary to renal disease (4 out of 4). Excluding these spe-
cific groups, the “abnormal” ACTH-dependent aldosterone
response is still found in 32% of the patients with recent onset
or inappropriate HBP (7 out of 22).
In summary we found that mild defects of the late stages
of adrenal steroidogenesis, involving the 21-hydroxylase and
the 11𝛽-hydroxylase enzymes, are very common in PA (28%)
and in EHBP (48%); these defects are characteristically
associated with an abnormal resetting of mineralocorticoid
production now depending on ACTH (>60%), which oth-
erwise even in the absence of apparent defects of adrenal
steroidogenesis is also very common in PA (57%) and in
EHBP (32%). At least one of these “abnormalities” is found in
79% of patients with PA and in 65% of patients with apparent
EHBP. These data are summarized in Figure 3, excluding the
small number of patients with renal disease.
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4. Discussion
Adrenal glands play a major role in the homeostasis of
blood pressure levels. Several specific adrenal diseases are
known as causes of secondary HBP, the most common one
being PA [1–3]. However a more general involvement of
adrenal steroidogenesis, mainly regarding mineralocorticoid
production and/or control, has been suggested in EHBP [8–
12].
This paper reports three major findings. (1) Mild defects
of the 21-hydroxylase and the 11-hydroxylase enzymes are
very common in inappropriate or recent onset HBP, even if
theoretically the first one is not mechanistically associated
with HBP. (2) Strong ACTH- dependence of aldosterone is
very common in the context of inappropriate HBP, either
EHBP or secondary forms of HBP, namely, PA and renal
disease. (3) This ACTH-dependence of aldosterone is char-
acteristic of mild defects of adrenal steroidogenesis, either
21-hydroxylase or 11-hydroxylase defects, being found in
almost two-thirds of such cases. The inappropriate resetting
of mineralocorticoid production and secretion may be a
relevant pathogenicmechanism forHBP andmay explain the
unexpected association of 21-hydroxylase defects with HBP.
We first report a high prevalence (22%) of apparent mild
11OHD in selected patients with inappropriate HBP. We used
a more restricted criterium of an S response greater than
10 ng/mL to cosyntropin, the same quantitative criterium that
is generally accepted for themore common 21OHD regarding
the 17OHP response. This restriction seems justified since
17OH/S ratios are always near to or greater than 1 [15, 16].
Several lines of evidence suggest that this mild defect is real:
(a) baseline S levels and stimulated S response to cosyntropin
do not fit a unimodal distribution and are not normally
distributed; (b) baseline values of S are higher than in the
group without the defect; (c) the stimulated cortisol/S ratio is
significantly lower suggesting indeed the decreased effective-
ness of 11-deoxycortisol to cortisol conversion; (d) as shown
patients with this mild apparent defect characteristically
present an ACTH-dependent aldosterone response (64%).
Of course this is not a major defect [4–6, 16–18]. The
classic 11OHD is a rather rare condition, occurring in only
1 : 20,000 live births and accounting for only 8% of all cases
of CAH. Furthermore the classic form presents with sexual
ambiguity, advanced growth albeit with limitation of final
height, precocious puberty, oligomenorrhea, and hirsutism.
Much more probably this mild defect that is only apparent
after supraphysiological stimulation corresponds to either
simple heterozygotes, which may be up to 100 times more
common although it is controversial whether such patients
present any endocrine abnormalities [19], compound het-
erozygotes, or common polymorphisms of the CYP11B1 gene
[11, 12, 20, 21]. Itmay even correspond to a secondary acquired
defect, although we are not aware of known modulators of
this enzyme activity besides glycyrrhizin acid or metyrapone
[3–7].
Genetic studies as well as measurement of specific steroid
compounds, like 11-deoxy corticosterone (DOC) and corti-
costerone, are necessary to further characterize these defects,
although very large samples will probably be needed given
both the mild nature of the defect and the probable genetic
heterogeneity.
Other authors have previously reported this mild defect
in patients with HBP and in patients with PA [8, 10–12,
20, 21]. Isolated reports also point to the association of this
mild defect with an apparent ACTH-dependent aldosterone
secretion [9]. Our data suggest that this is indeed a very
common association (66%). It should be noted that both the
increased levels of precursors withmineralocorticoid activity,
that is, deoxy corticosterone and the abnormal resetting of
mineralocorticoid production by ACTH, could contribute to
HBP.
We also report on an unexpectedly high frequency ofmild
21OHD (20%). An increased 17OHP response is found in
more patients, but these include patients with mild defects
of 11OHD which is of course not unexpected. It emphasizes
the need of the simultaneousmeasurement of S and 17OHP to
define 21OHD and may contribute to the reportedly low fre-
quency of the 11OHD; should only 17OH be measured, many
11OHD will instead be classified as 21OHD [4–6, 14]. Again
the same arguments may be made regarding the validity of
that defect, namely, the nonunimodality and nonnormality of
the 17OHP response, the decreased cortisol/17OH ratio, and,
up to a point, the ACTH-dependent aldosterone response.
Again, and for the same reasons as before, this is not a major
defect andmost probably corresponds either to heterozygotes
or to polymorphisms of the CYP21 gene, even if an acquired
defect cannot be excluded [4–6, 13, 21].
Two additional points characterize patients with apparent
mild 21OHD. In such a defect, S levels should be expected
to be decreased; instead in these patients, and regarding
patients without apparent defects of the steroidogenesis, S
levels are increased, albeit not to the level of that found in
patients with 11OHD. This suggests that these patients also
present a defective conversion of S to cortisol that is not
more evident given the presence of the 21OHD [14, 22–24].
Secondly, these patients also present an ACTH-dependent
aldosterone response that so far has not been previously
reported, except in single case reports [25]. Both the double
block, involving the 11-hydroxylase enzyme besides the 21-
hydroxylase enzyme, and the ACTH-dependent aldosterone
response could explain the otherwise paradoxical association
of the 21OHD with HBP. Interestingly enough, some recent
reports suggest increased systolic and/or diastolic blood
pressure levels in patients 21-hydroxylase deficiency with
systolic but not diastolic blood pressure levels being related to
body mass index, and neither being related to glucocorticoid
doses [26, 27].
The large frequency of 21OHD and 11OHD argues against
a genetic background; instead an adaptive response is sug-
gested. Teleologically, limitation of adrenal steroidogenesis,
by mild blockade at the 21-hydroxylase and 11𝛽-hydroxylase
enzymes, could be of value, in the context of HBP by lim-
iting final glucocorticoid and mineralocorticoid production.
However, as noted below, ACTH-dependent aldosterone pro-
duction could offset the protective effect of such a response.
Regarding patients with apparent mild 21-hydroxylase
and/or 11-hydroxylase defects, data regarding 24 h uri-
nary sodium and potassium excretion may be informative.
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Obtaining that data might require however strict control
of dietary ingestion or very large samples to allow for a
meaningful interpretation.
The third major finding was that an extremely com-
mon ACTH-dependent aldosterone secretion is operatively
defined as an aldosterone response greater than that of
cortisol in the cosyntropin test. This is new in the sense that
ACTH is generally assumed to be a minor factor controlling
aldosterone secretion, contrary to what happens in regard to
cortisol, since aldosterone secretion is mainly dependent on
the renin-angiotensin axis [4, 5, 28]. As noted the response
on the cosyntropin test clearly does not depend on renin.
We suppose that this is another way to look at the same
phenomenon of aldosterone suppression andHBP correction
by dexamethasone that is generally used to define GRA [29].
Themolecular basis of that difference resides in the promoter
of the CYP11B1 gene, with responsive elements for ACTH
and that of the CYP11B2 gene, with elements responsive to
renin. Unequal crossing over between adjacent CYP11B1 and
CYP11B2 genes that are very close on chromosome 8q21, 40 kb
apart, where the promoter regulatory region of the CYP11B1
gene is juxtaposed to the coding region of the CYP11B2 gene,
results in a chimeric enzyme, overexpressed in the fasciculata
zone, under the control of ACTH and to aldosterone excess
and HBP [30, 31]. However as described that is a very
rare disease with a completely different presentation, that is,
familial HBP, beginning very early in life and with a severe
course and early end organ damage [32–34]. Again this is
not probably what we found. However it should be noted
that ACTH-dependence of aldosterone secretion has been
noted without such genetic abnormalities [35], while it has
been also reported in patients with 11-hydroxylase defects
[8–10, 12, 21] and is characteristic of PA-adenoma [3] and
it is extremely unlikely that both those conditions would
also present that genetic defect. It seems more likely that
ACTH-dependent aldosterone secretion, as defined, results
from convergent signaling pathways from angiotensin II and
ACTH, respectively, phospholipase C and adenylyl cyclase
[36]. Cross-talk between these two activating systems may
be modulated by several cellular signals as shown recently
regarding Sprouty-related protein with EVH1 domain 2 [37].
In this report we found that ACTH-dependent aldos-
terone secretion is very common in EHBP or at least in the
highly selected group of the patients such as this one but
furthermore characterizes patients with disordered steroido-
genesis, 11-hydroxylase and 21-hydroxylase defects, patients
with PA either hyperplasia or adenoma, and patients with
HBP secondary to renal diseases. Of course such a general
aldosterone response to ACTH strongly argues against such
a defect; on the contrary it suggests some kind of regulatory
effect that makes the CYP11B2 gene responsive to ACTH.
Other authors have suggested the same possibility [8–12].
However the reason/mechanism for that response in the
other cases is unknown. Interestingly enough, both the
CYP11B1 and the CYP11B2 genes respond to intracellular
AMPc [3–5]. It seems therefore possible that mild defects
of steroidogenesis with the compensatory increased drive
of ACTH could result in a ACTH-dependent aldosterone
secretion. ACTH may also, in some cases at least, be
the stimulus driving PA-hyperplasia that may sometimes
evolve to adenoma [24]. It has been suggested that in a
significant group of hypertensive patients, probably up to 15%
with low renin levels, aldosterone may indeed be ACTH-
responsive [11, 12]. Whatever the reason, however, a CYP11B2
responsive to ACTH would theoretically, as in GRA, lead to
inappropriate aldosterone levels and HBP.
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